Science, Complicated Pharmacology, Patient Relationships Drew Alan Moss, M.D., to Crohn’s and Colitis
The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.
First of five parts
In an era of U.S. healthcare that can make for fleeting and fragmented relationships between patients and clinicians, Alan Moss, M.D., has had different experience, sometimes seeing patients over many years and different stages of their lives.
“I have had patients who were in high school, then they’re in college, and (then) they’re trying to carve out a career, they’re getting pregnant. And all those things bring up a whole new batch of questions,” Moss said in a recent wide-ranging interview with Managed Healthcare Executive.
The Crohn’s and Colitis Foundation announced on Sept. 25 that Moss had been named the organization’s chief scientific officer. Moss is also the director of the Crohn’s & Colitis Program at Boston Medical Center. Prior to Boston Medical Center, he conducted research and took care of patients at Beth Israel Deaconess Medical Center, which is also in Boston.
In addition to the enduring patient relationship, Moss said he was draw to a career in inflammatory bowel disease care and research by complexities of the scientific understanding of Crohn’s disease and ulcerative colitis and the pharmacology of the treatments.
In this video segment of his conversation with MHE, Moss also discusses the research, education and advocacy aspects of his new job at the Crohn’s and Colitis Foundation.
The Future of Ulcerative Colitis Treatment: Tremfya's Potential Unveiled
July 11th 2024Tremfya is an interleukin (IL)-23 and CD64-inhibiting monoclonal antibody. The FDA approved it in 2017 as a moderate to severe plaque psoriasis treatment. It has since been approved to treat psoriatic arthritis.
Read More
Stem-like T Cells: A Potential Target for Ulcerative Colitis Treatment
July 1st 2024A study published in Nature Immunology focused on understanding the origins of stem-like T cells in ulcerative colitis patients. By analyzing colon tissue samples from human patients, researchers found a significant population of stem-like T cells in inflamed regions of the large intestine compared to healthy individuals.
Read More
In a study recently published in BMJ Open Gastroenterology, researchers led by Pernille Dige Ovesen from the department of gastroenterology and hepatology in Copenhagen University Hospital investigated the effect of concomitant corticosteroid therapy on treatment outcomes in patients with UC initiating infliximab.
Read More
